Vericel Co. (NASDAQ:VCEL) CEO Dominick Colangelo Sells 26,592 Shares

Vericel Co. (NASDAQ:VCEL) CEO Dominick Colangelo sold 26,592 shares of Vericel stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $45.78, for a total transaction of $1,217,381.76. Following the sale, the chief executive officer now owns 259,997 shares in the company, valued at $11,902,662.66. This represents a 9.28 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Vericel Trading Down 0.0 %

Shares of NASDAQ:VCEL opened at $45.38 on Friday. The firm has a market cap of $2.27 billion, a PE ratio of 756.46 and a beta of 1.78. The company has a fifty day simple moving average of $55.59 and a 200 day simple moving average of $51.86. Vericel Co. has a 12-month low of $39.12 and a 12-month high of $63.00.

Hedge Funds Weigh In On Vericel

A number of hedge funds have recently added to or reduced their stakes in VCEL. Arcadia Investment Management Corp MI acquired a new position in Vericel in the fourth quarter worth $48,000. Farther Finance Advisors LLC boosted its holdings in Vericel by 48.1% in the third quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 405 shares during the period. GF Fund Management CO. LTD. acquired a new position in Vericel in the fourth quarter worth $57,000. Smartleaf Asset Management LLC boosted its holdings in Vericel by 511.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,265 shares of the biotechnology company’s stock worth $70,000 after purchasing an additional 1,058 shares during the period. Finally, Meeder Asset Management Inc. acquired a new position in shares of Vericel during the third quarter valued at $92,000.

Analyst Ratings Changes

VCEL has been the topic of a number of analyst reports. HC Wainwright reiterated a “buy” rating and set a $60.00 price objective on shares of Vericel in a research note on Friday, February 28th. StockNews.com upgraded shares of Vericel from a “sell” rating to a “hold” rating in a research note on Saturday, March 8th. Truist Financial reiterated a “buy” rating and set a $61.00 price objective (down previously from $67.00) on shares of Vericel in a research note on Monday, March 3rd. Canaccord Genuity Group lifted their price objective on shares of Vericel from $64.00 to $67.00 and gave the company a “buy” rating in a research note on Monday, February 3rd. Finally, BTIG Research lifted their price target on shares of Vericel from $56.00 to $66.00 and gave the stock a “buy” rating in a research note on Tuesday, November 26th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $62.29.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.